The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

"One aspect that's often overlooked is the role of medications. Blood thinners, such as aspirin or anticoagulants, can ...

School nurses, teachers or other people trained and qualified would be authorized to administer the nasal spray to a student or staff member experiencing symptoms of an opioid overdose.

A LETHAL Frankenstein narcotic that can kill its victims in the smallest of doses is increasingly being found in vapes and ...

In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles ...

Matternet, the developer of the world's leading urban drone delivery system, today announced that the company has been approved by The Kingdom of Saudi Arabia to operate its M2 drone within the region ...